Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published ...
PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has forwarded to Hemispherx both its Public Summary of Opinion (PSO) …